Pulmonary nodules and shadows can be seen under CT. The patient may be asymptomatic, but cough, hemoptysis, bloody sputum, chest pain, low-grade fever, emaciation, fatigue and other symptoms may occur
Conditions
Interventions
Control group:CT-guided implantation of Hookwire
Trial group:CT-guided implantation of fiducial markers
Sponsors
Wuhan Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.The age must be >= 18 years and <= 75 years; 2.The indication of VATS for pulmonary nodules clinically diagnosed; 3.those who volunteered to participate in the study and signed the informed consent form; 4.regardless of gender;
Exclusion criteria
Exclusion criteria: 1.patients with previous lung surgery; 2.patients with massive pleural effusion; 3.Leukopenia or thrombocytopenia (white blood cell < 3x10^9/L, platelet < 50x10^9/L); 4.those who are allergic to iodine or iodine-containing products; 5.patients who planned to undergo lobectomy; 6.patients scheduled for pneumonectomy; 7.pregnant or lactating women; 8.those who participated in other clinical trials within the past 3 months; 9.Others considered by the investigator to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Technical Success Rate of Labeling Agents; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs): Any unfavorable medical occurrence during the study, regardless of device relatedness, is an AE; an AE resulting in death or significant deterioration in health status is an SAE.;The researchers were satisfied with the product performance;The success rate of complete clearance of lesions; | — |
Countries
China
Contacts
Public ContactDai Xiyong
Wuhan Pulmonary Hospital
Outcome results
None listed